Risk Minimisation Material: Rinqov (upadacitinib) – Healthcare Professional Educational Brochure

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
20 December 2019

Abstract

This brochure contains safety information for consideration; namely risk of opportunistic infections including TB, varicella zoster reactivation, potential risk of cardiovascular or venous thromboembolic events and potential for birth defects if taken during pregnancy.